Pathology: malignant mesothelioma (mMS) - 1st line (L1); malignant mesothelioma (mMS) - 2nd line (L2);
| malignant mesothelioma (mMS) - 1st line (L1) | malignant mesothelioma (mMS) - 2nd line (L2) | |||
| CheckMate 743, 2021 | CONFIRM, 0 | DETERMINE, 2017 | ||
| nivolumab alone | 1 | T1 | ||
| nivolumab plus ipilimumab | 1 | T1 | ||
| tremelimumab | 1 | T1 | ||
| pemetrexed plus platin | 0 | T0 | ||
| placebo | 0 | T0 | T0 |